WO1987002131A1 - Whole blood clotting timer - Google Patents

Whole blood clotting timer Download PDF

Info

Publication number
WO1987002131A1
WO1987002131A1 PCT/AU1982/000180 AU8200180W WO8702131A1 WO 1987002131 A1 WO1987002131 A1 WO 1987002131A1 AU 8200180 W AU8200180 W AU 8200180W WO 8702131 A1 WO8702131 A1 WO 8702131A1
Authority
WO
WIPO (PCT)
Prior art keywords
blood
sample
optical density
time
clotting
Prior art date
Application number
PCT/AU1982/000180
Other languages
French (fr)
Inventor
Peter Craig Farrell
Christopher David Bertram
Bruce Kenneth Milthorpe
Original Assignee
Peter Craig Farrell
Christopher David Bertram
Bruce Kenneth Milthorpe
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Peter Craig Farrell, Christopher David Bertram, Bruce Kenneth Milthorpe filed Critical Peter Craig Farrell
Publication of WO1987002131A1 publication Critical patent/WO1987002131A1/en

Links

Classifications

    • GPHYSICS
    • G01MEASURING; TESTING
    • G01NINVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/483Physical analysis of biological material
    • G01N33/487Physical analysis of biological material of liquid biological material
    • G01N33/49Blood
    • G01N33/4905Determining clotting time of blood
    • GPHYSICS
    • G01MEASURING; TESTING
    • G01NINVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N15/00Investigating characteristics of particles; Investigating permeability, pore-volume, or surface-area of porous materials
    • G01N15/04Investigating sedimentation of particle suspensions
    • G01N15/05Investigating sedimentation of particle suspensions in blood

Definitions

  • the present invention relates to a whole blood clotting ti
  • Clinically blood clotting timers are used to (a) investigate and diagnose disorders of the blood clotting system which concerns bleeding disorders such as failure to clot, or thrombosis, that is, excessive or uncontrolled clotting, or (b) monitor the efficacy of anticoagulation therapy either in treatment of potential thrombosis or in extracorporeal blood circulation such as takes place during haemodialysis or open heart surgery.
  • Plasma is obtained by removing red cells by mechanical means such as a filter or a centrifuge. This has required the blood sample to be treated to inhibit the clotting mechanism, to have the red blood cells removed and to then have the clotting mechanism reactivated.
  • the clotting times of such reactivated samples differ systematically and greatly from those of whole blood mixed with activators, and the result is only available after an inconvenient delay.
  • the present invention relates to a device which combines the centrifugation and the optical sensing of clot formation into a single operation. This obviates the necessity to inhibit the clotting sequence thereby quickly giving activated clotting times on a par with those obtained mechanically from whole blood.
  • the present invention consists in a whole blood clotting timer comprising centrifuge means, means for mounting a whole blood sample within the centrifuge means, means to measure the optical density of the sample as the sample is being centrifuged, means to cause mixing of the whole blood sample with a blood clotting activator and means to measure the time between mixing of the blood with the clotting activator, or some other event which bears a reproducible time relationship with that event, and the time at which the centrifuged sample reaches a predetermined optical density or time rate of change of optical density or other optically pre-determined end-point corresponding to the time of clotting.
  • the present invention further consists in a method for determining the clotting time for a whole blood sample comprising mixing the blood with a blood clotting activator, centrifuging the mixture, measuring the optical density of a part of the mixture freed from blood cells as the mixture is centrifuged and measuring the time between the formation of the mixture, or some other event which bears a reproducible time relationship with that event, and the time at which optical density or time rate of change of optical density or other optical density criterion of the mixture reaches a predetermined level.
  • Centrifuges incorporating means for determining the optical density of a sample being centrifuged are known (see British Patent 1,405,694) however such centrifuges could not be used to measure the clotting time of whole blood and such centifuges do not include suitable timing means adapted to measure the time during which a predetermined change in the optical density of a sample occurs.
  • the present invention lies in the realisation that by the incorporation of suitable timing means with a centrifuge having optical density determining means a rapid and convenient determination of blood clotting times for whole blood may be determined.
  • the blood sample is mounted within the centrifuge in a disposable cuvette.
  • the cuvette preferably is so arranged that mixing of the blood sample and of an activator takes place by centrifugal action at a constant, and preferably very short time after the centrifuge is turned on.
  • This arrangement firstly has the advantage that no non-disposable parts come in contact with the blood which eliminates a major source of timing error.
  • This arrangement also allows the timer to be made quite small, allowing it to be readily transported to the patient. The simplicity of operation allows general nursing staff and, in the case of home haemodialysis patients, members of the public to use it with little training being required.
  • the cuvette used to hold the sample is at least transparent in a region inwardly of that end which is radially outermost when mounted in the centrifuge.
  • This region of the cuvette should coincide in use with a transparent window in the rotor to allow a light beam to shine through the cuvette and its contents once on each revolution of the centrifuge.
  • the optical density of the sample can thus be determined by measuring-the amount of light transmitted through the sample. Means need to be provided to ensure that the light transmittance is measured while the sample is in the light beam. This may be conveniently achieved by the use of a locating tab on the rotor intersecting another light beam to trigger the taking of an optical density reading.
  • the centrifuge may be of any suitable type, however, an electrically driven centrifuge rotating at up to 6000 rpm has been found to be most suitable.
  • the timing means and optical density determining means may be of any suitable type known in the art. Solid state electronic timing means are most conveniently used.
  • the sample In order to obtain as consistent results as possible it is desirable for the sample to be maintained at a predetermined temperature, most preferably 37 C, during the determination of the clotting time. If desired multiple determinations could be carried out simultaneously by having a plurality of samples being simultaneously or sequentially examined.
  • Fig. 1 is a diagrammatic cross sectional view through the centrifuge section of a whole blood clotting timer according to the present invention.
  • Fig. 2 is a perspective view of a cuvette for use in the centrifuge of Fig. 1.
  • the whole blood clotting timer 10 comprises a centrifuge 11, a cuvette 12 adapted to hold a blood sample and mountable on the rotor 13 of the centrifuge 11, a pair of collimating light sources 14 and corresponding light intensity detectors 15 and timing means 25.
  • the rotor 13 is driven by an electric motor 16 which runs at 6000 rpm.
  • the cuvette 12 is retained on the rotor 13 by a cuvette holder 17.
  • the weight of the cuvette 12 on the rotor is balanced by a diametrically opposed counter weight 18 from which projects a locating tab 19.
  • One collimated light source 14 is so disposed that it is vertically above the cuvette path such that the light beam will pass through a part of the cuvette spaced inwardly of its radially outer end, so as to avoid the beam being obscured by cells thrown to the end of the cuvette by centrifugal action, and through a window 21 in the rotor 13.
  • the intensity of the beam is measured by a corresponding one of the light detectors 15 and a signal fed, through means not shown, to the timer to cause the timer to stop when a predetermined time rate of change of optical density has been reached by the sample.
  • the timing of the reading of the optical density of the sample in the cuvette 12 is achieved by taking a reading as the tab 19 intersects the beam of the other light source 14.
  • a clotting activator such as thrombin is placed in an outer chamber 22 of the cuvette 12 and the cuvette placed in position on the rotor 13.
  • the blood sample is introduced into an inner chamber 23 and the centrifuge started which simultaneously starts the timing means. Centrifugal action substantially instantaneously forces the blood sample from the inner chamber 23 over a ridge 24 in the cuvette and into the outer chamber 22 with sufficient force to ensure complete mixing of the blood and the clotting activator.
  • the blood cells then rapidly settle at the outer edge of the sampling chamber leaving a region of clear plasma for interrogation by the light beam.
  • a reduction in the intensity of the light transmitted through the plasma to the detector 15 signals the onset of clotting and the timer is turned off. The time between the switching on and switching off of the centrifuge is then displayed on the timing means.

Abstract

A method and device for determining the clotting time for a sample of whole blood. A sample of whole blood is placed in a cuvette (12) which is centrifuged in a centrifuge (11) to mix the blood sample with a coagulant in the cuvette (12) and simultaneously spin out the cells in the blood. The optical density of a part of the sample which is cleared of cells by the centrifugation is monitored using a light source (14) and a light detector (15) and the time measured for optical density indicative of clotting to be reached by a timer (25).

Description

WHOLE BLOOD CLOTTING TIMER The present invention relates to a whole blood clotting ti Clinically blood clotting timers are used to (a) investigate and diagnose disorders of the blood clotting system which concerns bleeding disorders such as failure to clot, or thrombosis, that is, excessive or uncontrolled clotting, or (b) monitor the efficacy of anticoagulation therapy either in treatment of potential thrombosis or in extracorporeal blood circulation such as takes place during haemodialysis or open heart surgery.
Blood clotting time estimations are conventionally carried out manually although attempts have been made to automate them. Attempts at automation have either involved mechanical or optical methods for the detection of the formation of a gel-like clot. Optical sensing must, however, be performed on blood plasma rather than whole blood. Plasma is obtained by removing red cells by mechanical means such as a filter or a centrifuge. This has required the blood sample to be treated to inhibit the clotting mechanism, to have the red blood cells removed and to then have the clotting mechanism reactivated. The clotting times of such reactivated samples differ systematically and greatly from those of whole blood mixed with activators, and the result is only available after an inconvenient delay. The present invention relates to a device which combines the centrifugation and the optical sensing of clot formation into a single operation. This obviates the necessity to inhibit the clotting sequence thereby quickly giving activated clotting times on a par with those obtained mechanically from whole blood.
The present invention consists in a whole blood clotting timer comprising centrifuge means, means for mounting a whole blood sample within the centrifuge means, means to measure the optical density of the sample as the sample is being centrifuged, means to cause mixing of the whole blood sample with a blood clotting activator and means to measure the time between mixing of the blood with the clotting activator, or some other event which bears a reproducible time relationship with that event, and the time at which the centrifuged sample reaches a predetermined optical density or time rate of change of optical density or other optically pre-determined end-point corresponding to the time of clotting.
The present invention further consists in a method for determining the clotting time for a whole blood sample comprising mixing the blood with a blood clotting activator, centrifuging the mixture, measuring the optical density of a part of the mixture freed from blood cells as the mixture is centrifuged and measuring the time between the formation of the mixture, or some other event which bears a reproducible time relationship with that event, and the time at which optical density or time rate of change of optical density or other optical density criterion of the mixture reaches a predetermined level.
Centrifuges incorporating means for determining the optical density of a sample being centrifuged are known (see British Patent 1,405,694) however such centrifuges could not be used to measure the clotting time of whole blood and such centifuges do not include suitable timing means adapted to measure the time during which a predetermined change in the optical density of a sample occurs. The present invention lies in the realisation that by the incorporation of suitable timing means with a centrifuge having optical density determining means a rapid and convenient determination of blood clotting times for whole blood may be determined. In a preferred embodiment of the present invention the blood sample is mounted within the centrifuge in a disposable cuvette. In this arrangement the cuvette preferably is so arranged that mixing of the blood sample and of an activator takes place by centrifugal action at a constant, and preferably very short time after the centrifuge is turned on. This arrangement firstly has the advantage that no non-disposable parts come in contact with the blood which eliminates a major source of timing error. This arrangement also allows the timer to be made quite small, allowing it to be readily transported to the patient. The simplicity of operation allows general nursing staff and, in the case of home haemodialysis patients, members of the public to use it with little training being required.
In preferred embodiments of the invention the cuvette used to hold the sample is at least transparent in a region inwardly of that end which is radially outermost when mounted in the centrifuge. This region of the cuvette should coincide in use with a transparent window in the rotor to allow a light beam to shine through the cuvette and its contents once on each revolution of the centrifuge. The optical density of the sample can thus be determined by measuring-the amount of light transmitted through the sample. Means need to be provided to ensure that the light transmittance is measured while the sample is in the light beam. This may be conveniently achieved by the use of a locating tab on the rotor intersecting another light beam to trigger the taking of an optical density reading.
The centrifuge may be of any suitable type, however, an electrically driven centrifuge rotating at up to 6000 rpm has been found to be most suitable. The timing means and optical density determining means may be of any suitable type known in the art. Solid state electronic timing means are most conveniently used.
In order to obtain as consistent results as possible it is desirable for the sample to be maintained at a predetermined temperature, most preferably 37 C, during the determination of the clotting time. If desired multiple determinations could be carried out simultaneously by having a plurality of samples being simultaneously or sequentially examined. Hereinafter given by way of example only is a preferred embodiment of the present invention described with reference to the accompanying drawings in which:-
Fig. 1 is a diagrammatic cross sectional view through the centrifuge section of a whole blood clotting timer according to the present invention; and
Fig. 2 is a perspective view of a cuvette for use in the centrifuge of Fig. 1.
The whole blood clotting timer 10 comprises a centrifuge 11, a cuvette 12 adapted to hold a blood sample and mountable on the rotor 13 of the centrifuge 11, a pair of collimating light sources 14 and corresponding light intensity detectors 15 and timing means 25.
The rotor 13 is driven by an electric motor 16 which runs at 6000 rpm. The cuvette 12 is retained on the rotor 13 by a cuvette holder 17. The weight of the cuvette 12 on the rotor is balanced by a diametrically opposed counter weight 18 from which projects a locating tab 19.
One collimated light source 14 is so disposed that it is vertically above the cuvette path such that the light beam will pass through a part of the cuvette spaced inwardly of its radially outer end, so as to avoid the beam being obscured by cells thrown to the end of the cuvette by centrifugal action, and through a window 21 in the rotor 13. The intensity of the beam is measured by a corresponding one of the light detectors 15 and a signal fed, through means not shown, to the timer to cause the timer to stop when a predetermined time rate of change of optical density has been reached by the sample. The timing of the reading of the optical density of the sample in the cuvette 12 is achieved by taking a reading as the tab 19 intersects the beam of the other light source 14.
In use a clotting activator such as thrombin is placed in an outer chamber 22 of the cuvette 12 and the cuvette placed in position on the rotor 13. The blood sample is introduced into an inner chamber 23 and the centrifuge started which simultaneously starts the timing means. Centrifugal action substantially instantaneously forces the blood sample from the inner chamber 23 over a ridge 24 in the cuvette and into the outer chamber 22 with sufficient force to ensure complete mixing of the blood and the clotting activator. The blood cells then rapidly settle at the outer edge of the sampling chamber leaving a region of clear plasma for interrogation by the light beam. A reduction in the intensity of the light transmitted through the plasma to the detector 15 signals the onset of clotting and the timer is turned off. The time between the switching on and switching off of the centrifuge is then displayed on the timing means.

Claims

1. A whole blood clotting timer comprising centrifuge means, means for mounting a whole blood sample within the centrifuge means, means to measure the optical density of the sample as the sample is being centrifuged, means to cause mixing of the whole blood sample with a blood clotting activator and means to measure the time between mixing of the blood with the clotting activator, or some other event which bears a reproducible time relationship with that event, and the time at which the centrifuged sample reaches a predetermined optical density or time rate of change of optical density or other optically pre-determined end-point corresponding to the time of clotting.
2. A whole blood clotting timer as claimed in claim 1 in which the blood sample is mounted within the centrifuge means in a disposable cuvette which is at least transparent in a region inwardly of that end which is radially outermost when mounted in the centrifuge means such that the optical density of the sample in the cuvette may be measured.
3. A whole blood clotting timer as claimed in claim 2 in which the cuvette includes a first compartment and a second compartment containing a blood coagulant, the compartments being separated by a ridge in the floor of the cuvette, and the arrangement being such that upon insertion of the cuvette into the centifuge means with the second compartment radially outwardly and the insertion of a blood sample into the first compartment, actuation of the centrifuge means which cause the blood sample to flow over the ridge and mix with the blood coagulant in the second compartment.
4. A method for determining the clotting time for a whole blood sample comprising mixing the blood with a blood clotting activator, centrifuging the mixture, measuring the optical density of a part of the mixture freed from blood cells as the mixture is centrifuged and measuring the time between the formation of the mixture, or some other event which bears a reproducible time relationship with that event, and the time at which optical density or time rate of change of optical density or other optical density criterion of the mixture reaches a predetermined level.
PCT/AU1982/000180 1981-11-04 1982-11-04 Whole blood clotting timer WO1987002131A1 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
AU142281 1981-11-04
AUPF1422 1981-11-04

Publications (1)

Publication Number Publication Date
WO1987002131A1 true WO1987002131A1 (en) 1987-04-09

Family

ID=3691954

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/AU1982/000180 WO1987002131A1 (en) 1981-11-04 1982-11-04 Whole blood clotting timer

Country Status (1)

Country Link
WO (1) WO1987002131A1 (en)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0369168A1 (en) * 1988-10-31 1990-05-23 Holger Behnk Method and apparatus for investigating and measuring the clotting time of blood

Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB908050A (en) * 1959-08-10 1962-10-10 Evans Electroselenium Ltd An improved apparatus for testing liquid samples
US3593568A (en) * 1969-04-01 1971-07-20 Bio Dynamics Inc Prothrombin time measuring apparatus with means to start the timer in response to the initial decrement of optical transmissivity
GB1377658A (en) * 1970-12-09 1974-12-18 Lode Instr Nv Methods and devices for determining the onset of coagulation of blood
AU5802173A (en) * 1972-08-02 1975-01-16 United States Atomic Energy Commission Rotor having sample holding means
AU2600377A (en) * 1976-06-09 1978-12-14 Electro-Nucleonics Inc. Disposable cuvette array

Patent Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB908050A (en) * 1959-08-10 1962-10-10 Evans Electroselenium Ltd An improved apparatus for testing liquid samples
US3593568A (en) * 1969-04-01 1971-07-20 Bio Dynamics Inc Prothrombin time measuring apparatus with means to start the timer in response to the initial decrement of optical transmissivity
GB1377658A (en) * 1970-12-09 1974-12-18 Lode Instr Nv Methods and devices for determining the onset of coagulation of blood
AU5802173A (en) * 1972-08-02 1975-01-16 United States Atomic Energy Commission Rotor having sample holding means
AU2600377A (en) * 1976-06-09 1978-12-14 Electro-Nucleonics Inc. Disposable cuvette array

Cited By (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0369168A1 (en) * 1988-10-31 1990-05-23 Holger Behnk Method and apparatus for investigating and measuring the clotting time of blood
US5238854A (en) * 1988-10-31 1993-08-24 Holger Behnk Method for testing and measuring blood clotting time
US5284624A (en) * 1988-10-31 1994-02-08 Holger Behnk Method of, and apparatus for, testing and measuring blood clotting time

Similar Documents

Publication Publication Date Title
US4640896A (en) Whole blood clotting timer
US5149501A (en) Multichambered container and instrument for performing diagnostic tests
EP0353264B1 (en) Biological sample mixing apparatus and method
US7422905B2 (en) Blood coagulation test cartridge, system, and method
EP0727044B1 (en) Apparatus for assaying viscosity changes in fluid samples and method of conducting same
US4443408A (en) Apparatus for analyzing the influence of additive reagents upon the coagulation of blood
EP0240153B1 (en) Disposable temperature probe for photoactivation patient treatment system
US7399637B2 (en) Blood coagulation test cartridge, system, and method
CA1310624C (en) Fluid separation and processing device
US4981585A (en) Centrifuge system and fluid container therefor
EP0184242A2 (en) Method for measuring coagulation parameters
US4671939A (en) Apparatus for analyzing the influence of additive reagents upon the coagulation of blood and related methods
JPH08338840A (en) Method and apparatus for determination of sedimentation velocity of blood
US4551308A (en) Apparatus for analyzing the influence of additive reagents upon the coagulation of blood and related methods
CN108603888B (en) Platelet aggregation activity analysis apparatus, platelet aggregation activity analysis system, platelet aggregation activity analysis program, and platelet aggregation activity analysis method
IE42546B1 (en) Method for detection of thrombosis and prethrombsis
US6706536B1 (en) Method and apparatus for processing coagulation studies, chemistry procedures and the like
EP0245703A2 (en) Separator device
US3824841A (en) Method for sedimentation study
CA2322650A1 (en) Method of measuring erythrocyte sedimentation rate (esr) or plasma fibrinogen of a blood sample
WO1987002131A1 (en) Whole blood clotting timer
US3777172A (en) Method and apparatus for measuring the clumping of platelets in whole blood
RU2061953C1 (en) Method for qualitatively determining general coagulation activity of blood platelets
EP0259463A4 (en) Heparin assay.
CA1132365A (en) Cuvette array for analysers

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A1

Designated state(s): US